FOXA1 and acute myeloid leukemia: Collectively, our integrated evidence establishes RNF220 as a FOXA1-suppressed independent prognostic biomarker that accelerates AML progression through glycolytic/phenylalanine metabolic reprogramming and immune-metabolic evasion.